Platelets play a known role in the maintenance of vascular homeostasis, but these cells are emerging as important cellular mediators of acute and chronic inflammatory diseases. Platelets are key elements in the pathogenesis of acute and chronic liver disease associated with hepatitis B virus (HBV) infection by promoting the accumulation of virus-specific CD8
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platelets are the chief cellular mediators of hemostasis and thrombosis. 2 Ongoing discoveries highlight the central role of platelets in immunity and inflammation during health and disease. Relevant works that describe platelet contributions in immune functions and different inflammatory and immunemediated diseases are summarized in Table 1 . [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Additionally, platelets are the most abundant cell type with immune function in blood circulation (,200 000/ml and ,900 000/ml in humans and mice, respectively). 1 Platelet immunological functions are achieved by the expression of a variety of adhesion molecules and immune receptors on their membrane that are instrumental for interactions with the endothelium and different subsets of circulating leukocytes. 14, 15 For example, platelet activation induces the mobilization of Pselectin, which mediates interactions with cells that express its ligand, P-selectin glycoprotein ligand-1, such as neutrophils, monocytes and other leukocytes. 16, 17 Platelets also express several integrins, including aIIbb3, a2b1, a5b1 and a6b1, which promote interactions with endothelial cells, extracellular matrix components and leukocyte populations that express integrin ligands, such as intercellular adhesion molecule-1 and junctional adhesion molecules. 18, 19 Platelets also possess a wide array of preformed inflammatory molecules and immune mediators that are stored inside three different intracellular granules, defined as a-, d-and lgranules (Table 2) . 20 a-granules are the most abundant type, and platelet activation induces the release/exposure of a plethora of mediators on the platelet surface that promote homotypic and heterotypic cellular interactions (e.g., P-selectin), including the activation (e.g., CD40L) and recruitment of inflammatory cells to the site of inflammation (e.g., chemokines) and the expression of proteins that promote cellular proliferation and neo-angiogenesis (e.g., TGF-b, PDGF and VEGF) ( Table 2) . 21 In addition, platelets store electrondense structures called d-granules, or dense bodies, that contain nucleotides (e.g., ADP, ATP) (Table 2) 21 that are important to sustain secondary platelet activation and vasoactive molecules, such as histamine and serotonin, which are important for the maintenance of vascular tone (Table 2) . 22 Finally, l-granules (lysosomes) contain proteins with bactericidal properties, including collagenase, elastase and b-glucuronidase (Table 1) . 20 The storage of preformed molecules enables their Anti-platelet therapy in HBV chronic inflammation R Aiolfi and G Sitia rapid release upon activation, but platelets also synthesize inflammatory mediators, such as IL-1b, de novo (Table 2) . 23 In this scenario, platelets play an important role in the timely control of infections and inflammation by interacting with endothelial and immune cells and releasing/producing proinflammatory mediators. 10, 24, 25 However, interactions between platelets and inflammatory cells that are chronically maintained promote an excessive and detrimental inflammatory immune stimulation that may lead to immunopathology and tissue destruction.
PLATELETS IN ACUTE HEPATITIS
In addition to work that identified platelets as important contributors of inflammatory and immune-mediated diseases, our group identified platelets as important players in the pathogenesis of hepatitis B virus (HBV)-related liver disease by sustaining the intrahepatic accumulation of virus-specific T cells, the intrahepatic expression of pro-inflammatory cytokines (e.g., IFN-c) and chemotactic factors that promote the recruitment of antigen nonspecific inflammatory cells. 8 Specifically, we showed that platelets were detectable inside the liver necroinflammatory foci that are characteristic of acute liver disease, together with small numbers of virus-specific CD8
1 T cells and nonspecific inflammatory cells that contribute to disease pathogenesis using two different models of acute viral hepatitis, HBV-replicating mice injected with HBV-specific CD8
1 T cells and wild-type mice infected with an hepatotropic adenovirus. 8 Notably, platelet depletion reduced the intrahepatic accumulation of virus-specific effector CD8
1 T cells and nonspecific inflammatory cells that were secondarily recruited and ultimately ameliorated the severity of liver disease. 8 
ANTI-PLATELET THERAPY AMELIORATES ACUTE AND CHRONIC VIRAL HEPATITIS
The exact mechanism by which platelets sustain the recruitment of inflammatory cells into the liver is not known, but we found that two platelet-specific activation inhibitors, aspirin, which blocks thromboxane A 2 production, and clopidogrel, which blocks the P2Y 12 ADP receptor, 26 reduced the accumulation of virus-specific CD8 1 T cells in the liver and the associated liver damage when administered alone or as a combination therapy. These results identified a functional link between platelets and virus-specific CD8 1 T cells. 27 Long-term oral aspirin and clopidogrel are used in patients who are at risk of thrombosis. Therefore, we took advantage of a previously established mouse model of immune-mediated chronic hepatitis B 28 to determine whether the sustained inhibition of platelet activation reduces the severity of chronic liver injury and its life-threatening complications, including cirrhosis and hepatocellular carcinoma (HCC). Chronic hepatitis B is characterized by a functionally inefficient virus-specific CD8 1 T-cell response that fails to eliminate HBV from the liver but maintains continuous cycles of low-level hepatocellular death and compensatory hepatocellular proliferation. These cycles are the driving force for the random genetic alterations that occur over several decades in an environment enriched with inflammatory mutagens, which induces HCC (Figure 1a) . 29 Alternative mechanisms of carcinogenesis that are often attributed to HBV, such as HBV DNA integration (inside or in the proximity of genes that control cellular proliferation, survival and differentiation), and the expression of pro-carcinogenic viral products (e.g., HBx and HBs) 30 represent additional factors of hepatocarcinogenesis that are secondary to the chronic inflammation mediated by virus-specific T cells. 29 Notably, the inhibition of platelet activation pathways using clinically achievable doses of the anti-platelet drugs aspirin and clopidogrel, which are continuously administered after the induction of acute hepatitis, reduces the intrahepatic accumulation of virus-specific CD8
1 T cells and the secondary recruitment of additional pathogenic antigen nonspecific inflammatory cells, which prevents overall hepatocarcinogenesis and greatly improves survival in this model system (Figure 1b) . 31 Mechanistically, aspirin treatment at clinically relevant doses has no direct anti-inflammatory ability, 26 but it inhibits the release of serotonin and other small molecules from d-granules. Aspirin has no effect on the release of proteins and peptides stored in a-granules, which are potentially important in the cross-talk between platelets and virus-specific CD8
1 T cells. 6, 16, 24 Conversely, clopidogrel inhibits the expression of a-granule-stored proteins that are involved in heterotypic interactions between platelets/leukocytes and the endothelium, such as P-selectin and CD40L. 32 These observations suggest that the combined use of aspirin and clopidogrel ameliorates the course of immune-mediated chronic hepatitis and HCC progression through distinct pharmacological effects. The synergistic action of these two drugs may represent a new therapeutic strategy to reduce the platelet-dependent accumulation of pathogenic virus-specific CD8 1 T cells, and consequently, the accumulation of virus-nonspecific inflammatory cells, hepatocellular injury and compensatory proliferation, liver fibrosis and HCC development.
These results support the hypothesis that a sustained immune-mediated necro-inflammatory liver disease involving platelets is responsible for the development of HCC in an HBV transgenic mouse model. The results also suggest that similar events are responsible for the development of HCC in chronically infected patients. 31, 33 Notably, anti-platelet therapy does not appear to act on alternative platelet-derived pro-tumoral factors that are implicated in the pathogenesis of chemically induced HCC. 31 Accordingly, anti-platelet therapy did not reduce PDGF and VEGF 31 or overall HCC development in CCl 4 -induced hepatocarcinogenesis, a model in which transformation is independent of adaptive immune responses. These results further sustain the concept that a harmful virus-specific immune response is necessary and sufficient to drive liver cancer during chronic infections with a hepatotropic virus, such as HBV. 31 
CONCLUDING REMARKS
Clinically, anti-platelet therapy may represent a novel fascinating approach for the management of patients who are chronically infected with HBV. We believe that patients in the initial and active phases of the disease (e.g., high ALT) may represent ideal targets who may benefit the most from the long-term daily administration of anti-platelet therapy. Aspirin and clopidogrel reduced the intrahepatic recruitment of virus-specific CD8 1 T cells and secondarily recruited antigen nonspecific inflammatory cells, which may negatively impact the control of HBV replication. Therefore, caution must be taken during the administration of these drugs, and HBV viremia must be carefully monitored. In this view, combined aspirin-clopidogrel therapy may firstly be associated with antiviral therapy to control viral replication and reduce overall liver inflammation. An additional concern about this treatment is an increased risk of bleeding in individuals with compromised coagulation associated with impaired liver function. However, limiting treatment to patients who are at a low risk of bleeding during the early stages of chronic disease may be beneficial in reducing thrombosis, which is often observed in selected groups of patients with pro-coagulant imbalance. 34 Finally, the use of aspirin may reduce the risk of HCC in patients affected by chronic liver disease of unspecified etiologies, as recently reported. 35 These results are observational, with no randomization and flawed by confounding factors, but coupled with our preclinical findings, they strengthen the rationale for the design of future clinical trials to define the impact of antiplatelet therapy in chronically infected HBV patients.
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